SNPMiner Trials by Shray Alag

SNPMiner SNPMiner Trials (Home Page)

Report for Clinical Trial NCT01233115

Developed by Shray Alag, 2020.
SNP Clinical Trial Gene

LOC387715/HTRA1 Variants and the Response to Combined Photodynamic Therapy With Intravitreal Bevacizumab in Polypoidal Choroidal Vasculopathy

This study is to investigate whether there is an association of the LOC387715/HTRA1 variants with response to treatment with combined photodynamic therapy and intravitreal bevacizumab for patients with polypoidal choroidal vasculopathy.

NCT01233115 Age-Related Macular Degeneration
MeSH:Macular Degeneration

Primary Outcomes

Description: Best-corrected visual acuity (BCVA) using the Snellen chart was evaluated including BCVA up to 12 months

Measure: Best-corrected visual acuity

Time: up to 12 months

Secondary Outcomes

Description: Fluorescein angiography (FA) and ICGA (HRA; Heidelberg Engineering, Dossenheim, Germany) was evaluated. Greatest linear dimension (GLD) was determined based on both FA and ICGA.

Measure: Angiographic characteristics

Time: up to 12 months
Time Perspective: Retrospective

Cohort

There are 2 SNPs

SNPs

1 rs10490924

Patients were genotyped for the LOC387715 (rs10490924) and the HTRA1 gene polymorphism (rs11200638).

2 rs11200638

Patients were genotyped for the LOC387715 (rs10490924) and the HTRA1 gene polymorphism (rs11200638).


HPO Nodes